Grifols (NASDAQ:GRFS) Stock Passes Below 200-Day Moving Average – Should You Sell?

08 Jul 2026, 03:41 by Jessica Moore · The Cerbat Gem

Grifols, S.A. (NASDAQ:GRFS – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $8.37 and traded as low as $7.13. Grifols shares last traded at $7.21, with a volume of 976,362 shares traded.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GRFS. Wall Street Zen lowered Grifols from a “buy” rating to a “hold” rating in a research report on Monday, May 18th. Weiss Ratings downgraded Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Finally, Zacks Research lowered Grifols from a “hold” rating to a “strong sell” rating in a research note on Friday, May 8th. Two analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $10.00.

View Our Latest Analysis on GRFS

Grifols Stock Performance

The company has a debt-to-equity ratio of 1.16, a current ratio of 2.47 and a quick ratio of 0.85. The company’s 50-day moving average price is $7.66 and its two-hundred day moving average price is $8.37. The company has a market capitalization of $4.91 billion, a price-to-earnings ratio of 37.95, a PEG ratio of 0.28 and a beta of 0.67.

Grifols Dividend Announcement

The company also recently declared a special dividend, which will be paid on Thursday, July 9th. Shareholders of record on Thursday, July 2nd will be given a dividend of $0.0945 per share. The ex-dividend date of this dividend is Thursday, July 2nd. Grifols’s dividend payout ratio is 110.53%.

Hedge Funds Weigh In On Grifols

A number of institutional investors and hedge funds have recently modified their holdings of GRFS. Royal Bank of Canada increased its stake in shares of Grifols by 21.7% in the 1st quarter. Royal Bank of Canada now owns 486,824 shares of the biotechnology company’s stock valued at $3,461,000 after acquiring an additional 86,768 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Grifols in the first quarter worth $184,000. Goldman Sachs Group Inc. grew its holdings in Grifols by 1.9% in the first quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company’s stock worth $29,948,000 after purchasing an additional 80,507 shares during the period. EverSource Wealth Advisors LLC increased its stake in Grifols by 127.4% in the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 4,604 shares in the last quarter. Finally, Sei Investments Co. increased its stake in Grifols by 11.6% in the second quarter. Sei Investments Co. now owns 2,081,535 shares of the biotechnology company’s stock valued at $18,817,000 after purchasing an additional 216,793 shares in the last quarter.

Grifols Company Profile

(Get Free Report)

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.